Ipsen stock
Price history
+27.34% over the period1 year: from €126.90 (November 20, 2025) to €161.60 (November 20, 2026), +27.34%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | €161.60 |
| October 30, 2026 | €157.60 |
| September 30, 2026 | €142.10 |
| August 31, 2026 | €163.10 |
| July 31, 2026 | €167.20 |
| June 30, 2026 | €168.80 |
| May 29, 2026 | €156.60 |
| April 30, 2026 | €167.00 |
| March 31, 2026 | €160.40 |
| February 27, 2026 | €165.10 |
| January 30, 2026 | €137.60 |
| December 31, 2025 | €119.00 |
| November 28, 2025 | €124.30 |
| November 20, 2025 | €126.90 |
At a glance
The company
Biopharmaceutical company developing and commercializing medicines in oncology, rare diseases, and neuroscience across multiple markets
Latest results
Quarter to September 30, 2026
Next event
TickerLandia's take on Ipsen
- Pricier than usual relative to earnings: P/E on the latest fiscal year 30 vs a median of 22 over its last 9 fiscal years.
- Priced in line with similar companies: trailing 12-month P/E 26 vs 24 (+7%) in a group of 11.
- Strong point: Market momentum (65/100 in its group). Weak point: Dividend (39/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−7.13% from the 52-week high
Analysts · 13 analysts
Average target€162.23+0.39% vs. price
Buy 4 · Hold 6 · Sell 3 · Hold
TickerLandia Fingerprint: Ipsen
Compared with similar companies: low risk, strong momentum, and low price.
Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricelow35
How much it costs relative to what it produces.
Metric Value Position in group EV/EBITDA 8.32 15 Forward P/E 11.2 13 Price/book 2.83 45 Price/sales 3.10 51 P/E (trailing 12 months) 26.1 53 Profitabilityhigh63
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 27.4% 73 ROE 11.4% 40 ROA 10.3% 78 Gross margin 81.0% 83 Net margin 11.9% 40 Earnings stabilityaverage52
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 3.9% 41 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Growthhigh63
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +18.70% 69 Average revenue growth (3 years) +7.57% 49 Earnings growth (year over year) +21.50% 73 Financial strengthhigh63
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Current ratio 1.97 47 Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −0.42 77 Interest coverage 28.4 58 Debt/equitycounts in reverse: lower means more financial strength 0.20 69 Dividendlow39
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years at least 21 years 56 Dividend yield 1.0% 34 Payout ratio 25.9% 27 Market momentumstrong65
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +5.45% 65 Relative strength (6 months) +3.68% 62 Distance from 200-day average +1.91% 59 1-year return +27.34% 75 Risklow28
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 19.3% 29 Volatility (60 days) 25.4% 40 Beta (1 year) 0.32 13
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Ipsen is pricier than in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), Ipsen's P/E today is 30.4, above the median of its last 9 fiscal years (22.4; between 10.3 and 30.6 from 2016 to 2025). Ipsen's P/E (trailing 12 months): 26.1, +7% against the median of a group of 11 similar companies (24.5).
Compared with 11 similar companies
| Metric | Ipsen | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 26.1 | Middle | |
| Forward P/E | 11.2 | Low | |
| Operating margin | 27.4% | High | |
| ROE | 11.4% | Middle | |
| Debt/equity | 0.20 | Low |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Ipsen. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€2.3B
Latest quarter · Q2 2026
Net income
€403.1M
Latest quarter · Q2 2026
Quarterly net margin
17.5%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- €13.31B
- P/E
- 26.1
- EPS
- €6.18
- Volume
- 23.16K
- Daily trading
- €16.5M
- Dividend yield
- 0.99%
- Last ex-dividend on June 3, 2026
How Ipsen is changing
All resultsRevenue grew 7.9% a year on average over the last 5 years
Operating margin fell from 29.9% to 26.1%
Profits turn into cash: free cash flow equal to 176% of net income
Returns
Ipsen returns with dividends
€1,000 invested in Ipsen 5 years ago, on November 22, 2021, would be worth €1,905 today with dividends reinvested: +90.50% in total, +13.78% per year. On price alone it would be €1,799 (+79.88%).
| Period | Ipsen | CAC 40 | €1,000 becomes |
|---|---|---|---|
| 1 month | +6.39% | +1.14% | €1,064 |
| 6 months | +1.25% | −2.34% | €1,013 |
| Year to date | +35.80% | −2.72% | €1,358 |
| 1 year | +28.69% | −0.67% | €1,287 |
| 3 years | +60.58% | +9.39% | €1,606 |
| 5 years | +90.50% | +11.58% | €1,905 |
| 10 years | +185.62% | +75.02% | €2,856 |
Over the last 6 months it has done better than 27% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. CAC 40: price only. Calculate your investment
The chart in detail
Ipsen: technical analysis
Ipsen shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 6.5% below its all-time closing high (€172.90, May 6, 2026).
- Trend
- No clear trend
- RSI (14 sessions)
- 56
- Between 30 and 70
- vs 200-session average
- +1.91%
Support and resistance
Price areas where Ipsen has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance€173.40+7.30%3 touches, last on July 31, 2026
- Resistance€170.60+5.57%3 touches, last on November 12, 2026
- Last price€161.60
- Support€158.90−1.67%3 touches, last on June 8, 2026
- Support€155.90−3.53%2 touches, last on July 24, 2026
- Support€152.93−5.36%3 touches, last on August 12, 2026
Volatility and risk
Over the last year it has moved little with the CAC 40.
- Beta (1 year) vs CAC 40
- 0.32
- Volatility (60 sessions, annualised)
- 25.4%
- Largest fall in the last year
- −19.26%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Ipsen: seasonality
Average monthly price change over 21 years
Over the last 21 years, the strongest month for Ipsen has been April: +5.51% on average, positive in 15 years out of 21. The weakest has been June: −2.94% on average, positive in 8 years out of 21. November, the current month, has been positive in 11 years out of 20 (+0.10% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +1.75% | +4.37% | 12 of 21 |
| February | +3.03% | +0.03% | 11 of 21 |
| March | +0.33% | +0.49% | 11 of 21 |
| April | +5.51% | +5.93% | 15 of 21 |
| May | +2.06% | +2.69% | 15 of 21 |
| June | −2.94% | −2.51% | 8 of 21 |
| July | +1.44% | +2.57% | 14 of 21 |
| August | +1.89% | +3.12% | 12 of 21 |
| September | −1.00% | −0.35% | 9 of 21 |
| October | +1.05% | +3.65% | 14 of 21 |
| November | +0.10% | +1.81% | 11 of 20 |
| December | −0.11% | +1.22% | 11 of 20 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Ipsen and its competitors
Ipsen is best known for Somatuline, Dysport and Decapeptyl, with Cabometyx, Onivyde, Bylvay, Iqirvo and Sohonos also among its marketed or developed medicines. The biopharmaceutical group develops and commercializes treatments in oncology, rare disease and neuroscience, selling them in North America, Europe and other international markets. Its pipeline includes candidates in Phase III trials for follicular lymphoma and pediatric low-grade gliomas, as well as earlier-stage programs in solid tumors and aesthetic indications.
- Headquarters
- Paris, France
- Employees
- 5,535
- Founded
- 1929
- Chief executive
- David Loew
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| IpsenIPN | $14.63B | 27.4% | 26.1 | +1.25% |
| Swedish Orphan BiovitrumSOBI | $15.83B | 30.9% | 24.5 | +6.32% |
| H. LundbeckHLUN.A | $8.56B | 24.4% | 14.4 | +63.06% |
| HaleonHLN | $39.73B | 23.5% | 19.2 | +1.20% |
| Sandoz GroupSDZ | $41.51B | 9.3% | 68.8 | +22.19% |
| Galderma GroupGALD | $50.81B | 19.1% | 63.1 | +14.60% |
Same industry or related industries, similar size. Compare Ipsen with its competitors · Full profile
